https://www.regulatoryrapporteur.org/cpd-supplements/understanding-the-basics-of-atmp-regulation/99.article 2024-01-02T12:25:54.720Z https://www.regulatoryrapporteur.org/cpd-supplements/case-study-luxturna/100.article 2023-05-02T15:50:40.160Z https://www.regulatoryrapporteur.org/cpd-supplements/the-eu-clinical-trial-regulation-eu-no-536/2014-the-clinical-trials-information-system/97.article 2023-05-02T15:50:40.160Z https://www.regulatoryrapporteur.org/cpd-supplements/ctis-national-pilot-belgium/98.article 2023-05-02T15:50:40.160Z https://www.regulatoryrapporteur.org/cpd-supplements/fundamentals-of-regulatory-writing-the-document-development-process/96.article 2024-01-02T14:43:54.307Z https://www.regulatoryrapporteur.org/cpd-supplements/digital-health-technologies-an-overview-of-eu-and-us-frameworks/34.article 2023-05-02T15:50:40.160Z https://www.regulatoryrapporteur.org/cpd-supplements/qualification-of-stride-velocity-endpoint-in-duchenne-muscular-dystrophy-/35.article 2023-05-02T15:50:40.160Z https://www.regulatoryrapporteur.org/main-navigation/listening-is-only-the-first-step/63.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/meetings-reports/ivd5-how-do-i-implement-ivdr-some-key-practicalities/64.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/editorials/a-regulatory-revolution-driven-by-data/53.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/meetings-reports/hm10-scenarios-to-consider-risk/54.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/meetings-reports/hm1-spotlight-on-cee-challenges-and-opportunities-in-the-region/73.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/meetings-reports/hm2-fireside-chat-with-emer-cooke-a-review-of-current-and-future-priorities/57.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/meetings-reports/hm3-evolution-of-ema-eunethta-collaboration-across-decision-makers/81.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/meetings-reports/hm4-real-world-evidence-in-regulatory-decision-making/61.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/meetings-reports/hm5-reliance-worksharing-and-recognition-as-21st-century-regulatory-tools/58.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/meetings-reports/hm6-clinical-trials-of-the-future-patient-orientated-and-digitally-connected/76.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/meetings-reports/hm7-regulatory-progress-in-delivering-on-the-promise-of-atmps/52.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/meetings-reports/hm8-enhancing-dialogue-to-foster-innovation/62.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/meetings-reports/vm1-regulatory-science-focus-on-biologicals/56.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/meetings-reports/vm2-encouraging-specific-investments/59.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/meetings-reports/vm3-regulation-2019/6-on-antimicrobials-requirements-and-availability/75.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/main-navigation/vm4-practical-implementation-of-the-union-product-database/45.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/vm5-post-authorisation-under-regulation-2019/6/66.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/meetings-reports/md1-mdr-implementation-is-there-a-future-for-legacy-devices/60.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/meetings-reports/md2-global-development-strategy-which-market-should-you-go-to-first/82.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/meetings-reports/md3-digitalisation-how-to-bring-paradise-into-regulatory-work/55.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/main-navigation/md4-clinical-investigations-is-coordinated-ca-assessment-the-future/51.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/meetings-reports/md5-innovation-in-drug-device-combinations/49.article 2024-02-14T14:33:34.553Z https://www.regulatoryrapporteur.org/meetings-reports/ivd3-eu-implementation-current-state/50.article 2025-04-09T10:48:32.233Z https://www.regulatoryrapporteur.org/interviews/facilitating-the-use-of-information-to-improve-global-health/33.article 2024-02-14T14:35:16.750Z https://www.regulatoryrapporteur.org/clinical-trials/clinical-trial-information-system-overview-opportunities-and-challenges/36.article 2024-02-14T14:35:16.750Z https://www.regulatoryrapporteur.org/clinical-trials/on-the-path-to-adoption-of-decentralised-clinical-trials/37.article 2024-02-14T14:35:16.750Z https://www.regulatoryrapporteur.org/pharmaceuticals/nonclinical-immunogenicity-evaluation-in-toxicology-studies-of-biopharmaceuticals/41.article 2026-03-04T17:20:48.090Z https://www.regulatoryrapporteur.org/pharmaceuticals/a-regulatory-lens-on-an-industry-imperative-diversity-in-clinical-research/29.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/main-navigation/the-emas-veterinary-big-data-stakeholder-forum-part-1/39.article 2024-02-14T14:35:16.750Z https://www.regulatoryrapporteur.org/editorials/what-does-2022-have-in-store-for-clinical-trials/28.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/medical-devices/substance-based-medical-devices-regulatory-challenges-and-prospects/44.article 2024-02-14T14:35:16.750Z https://www.regulatoryrapporteur.org/pharmaceuticals/requirements-for-the-good-distribution-practice-of-medicinal-products/40.article 2024-02-14T14:35:16.750Z